IVIG and SCIG products comparison
ImmunoglobulinClinical comparison of all FDA-approved immunoglobulin products for providers. Compare concentration, IgA content, stabilizer, sugar content, osmolality, storage, FDA-approved indications, and compatibility considerations. Sources: FDA prescribing information.
Select any two to compare side by side
All products in this comparison
| Product | Manufacturer | Route | Frequency | Concentration | IgA Content | Stabilizer | Sugar Content | Osmolality | pH | Storage | FDA Indications | Contraindications | Compatibility Notes | Glucose Monitoring | Key difference |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Privigen | CSL Behring | IV | Every 3–4 weeks | 10% | ≤25 mcg/mL | L-proline | None | 320 mOsmol/kg | 4.8 | Room temp (up to 36 months) or refrigerated | PIDD, CIDP | IgA deficiency with anti-IgA antibodies; hyperprolinemia; severe hypersensitivity | No sucrose: preferred for renal risk patients | No interference (no maltose) | L-proline stabilized; very low IgA (≤25 mcg/mL); no sugar; FDA-approved for CIDP and PIDD |
| Gamunex-C | Grifols | IV / SC | Every 3–4 weeks (IV) or weekly (SC) | 10% | 46 mcg/mL average | Glycine (caprylate/chromatography purified) | None | 258 mOsmol/kg | 4.0–4.5 | Refrigerated; room temp up to 6 months | PIDD, CIDP, ITP | IgA deficiency with anti-IgA antibodies; hypersensitivity | No sucrose: preferred for renal risk patients; also approved for SC use | No interference (no maltose) | Dual IV/SC route; caprylate-stabilized; approved for CIDP, PIDD, ITP |
| Gammagard Liquid | Takeda | IV / SC | Every 3–4 weeks (IV) or weekly (SC) | 10% | 37 mcg/mL average | Glycine | None | 240–300 mOsmol/kg | 4.6–5.1 | Refrigerated (up to 36 months); room temp up to 9 months | PIDD (IV and SC), MMN (IV) | IgA deficiency with anti-IgA antibodies; hypersensitivity; corn allergy (trace) | Only IVIG with FDA-approved MMN indication; no sucrose | No interference | Dual IV/SC route; glycine-stabilized; 10% concentration |
| Gammagard S/D | Takeda | IV | Every 3–4 weeks | 5% or 10% (reconstituted) | <1 mcg/mL (5%), lowest available | Glucose, glycine, PEG | SUCROSE, renal risk | 636 mOsmol/kg (10%) | 6.4–7.2 | Room temperature (lyophilized) | PIDD, ITP, Kawasaki, B-cell CLL | IgA deficiency with anti-IgA antibodies; renal insufficiency (sucrose risk); hypersensitivity | ⚠️ Contains sucrose, avoid in renal impairment. Preferred for IgA-deficient patients (lowest IgA) | No maltose interference but monitor renal function | Lyophilized; lowest IgA option; 5% or 10%; CONTAINS SUCROSE |
| Octagam | Octapharma | IV | Every 3–4 weeks | 5% and 10% | ≤200 mcg/mL (10%) | Maltose (5%); no sugar (10%) | 5%: maltose; 10%: none | 310–380 mOsmol/kg | 5.1–6.0 | Refrigerated; room temp up to 18 months (10%) | PIDD (5% and 10%), ITP (10%) | IgA deficiency with anti-IgA antibodies; hypersensitivity | ⚠️ 5% contains maltose: can cause falsely elevated blood glucose readings with GDH-PQQ test strips. Use glucose-specific monitors only | ⚠️ 5%: maltose interferes with GDH-PQQ glucose tests | 5% and 10%; maltose-containing (5%); caution with glucose monitoring |
| Gammaplex | Grifols | IV | Every 3–4 weeks | 5% and 10% | <10 mcg/mL (5%); ≤20 mcg/mL (10%) | Sorbitol | None | 420–520 mOsmol/kg | 4.8–5.1 | Refrigerated; room temp up to 24 months (10%) | PIDD, ITP | IgA deficiency with anti-IgA antibodies; hereditary fructose intolerance (contains sorbitol); hypersensitivity | ⚠️ Contains sorbitol: contraindicated in hereditary fructose intolerance | No interference | 5% and 10%; sorbitol-stabilized; no sugar; approved for PIDD and ITP |
| Panzyga | Octapharma | IV | Every 3–4 weeks | 10% | ≤100 mcg/mL | Glycine | None | 240–310 mOsmol/kg | 4.5–5.0 | Refrigerated; room temp up to 24 months | PIDD, ITP | IgA deficiency with anti-IgA antibodies; hypersensitivity | No sucrose, no maltose: no special renal or glucose concerns | No interference | 10%; glycine-stabilized; approved for PIDD and ITP |
| Bivigam | ADMA Biologics | IV | Every 3–4 weeks | 10% | Not specified (traces) | Glycine | None | 267–378 mOsmol/kg | 4.0–4.6 | Refrigerated | PIDD | IgA deficiency with anti-IgA antibodies; hypersensitivity | No sucrose, no maltose | No interference | 10% liquid; glycine-stabilized; approved for PIDD |
| Asceniv | ADMA Biologics | IV | Every 3–4 weeks | 10% | Not specified (traces) | Glycine, polysorbate 80 | None | 270–390 mOsmol/kg | 4.5–4.9 | Refrigerated | PIDD | IgA deficiency with anti-IgA antibodies; hypersensitivity | Unique: standardized anti-pneumococcal antibody levels, may benefit recurrent infection patients | No interference | Standardized high-titer anti-pneumococcal antibodies; for PIDD patients with recurrent infections |
| Flebogamma DIF | Grifols | IV | Every 3–4 weeks | 5% and 10% | ≤50 mcg/mL | D-sorbitol (5%); none (10%) | None | 240–370 mOsmol/kg | 5.0–6.0 | Room temperature up to 24 months | PIDD | IgA deficiency with anti-IgA antibodies; hypersensitivity | Room temp storage advantage | No interference | 5% and 10%; sorbitol-free (unlike Gammaplex); D-sorbitol–free formulation |
| Gammaked | Grifols | IV / SC | Every 3–4 weeks (IV) or weekly (SC) | 10% | 46 mcg/mL average | Glycine | None | 258 mOsmol/kg | 4.0–4.5 | Refrigerated; room temp up to 6 months | PIDD, CIDP, ITP | IgA deficiency with anti-IgA antibodies; hypersensitivity | Essentially same product as Gamunex-C (different brand name/distributor) | No interference | Dual IV/SC route; same formulation as Gamunex-C; approved for CIDP, PIDD, ITP |
| Hizentra | CSL Behring | SC | Weekly or biweekly | 20% | ≤50 mcg/mL | L-proline | None | 380 mOsmol/kg | 4.6–5.2 | Room temperature up to 30 months | PIDD, CIDP | IgA deficiency with anti-IgA antibodies; hyperprolinemia; hypersensitivity | ⚠️ Contains L-proline: contraindicated in hyperprolinemia. Preferred for home infusion | No interference | 20% SC; home self-infusion; L-proline stabilized; approved for PIDD and CIDP |
| HyQvia | Takeda | SC (facilitated) | Monthly | 10% IG + hyaluronidase | 37 mcg/mL average | Glycine + hyaluronidase component | None | 240–300 mOsmol/kg | 4.6–5.1 | Refrigerated | PIDD | IgA deficiency with anti-IgA antibodies; hypersensitivity to hyaluronidase | Only monthly SC option: significant convenience advantage. Hyaluronidase allows larger volume SC infusion | No interference | Monthly SC dosing via recombinant hyaluronidase; approved for PIDD |
| Cuvitru | Takeda | SC | Weekly | 20% | 80 mcg/mL average | Glycine | None | 210–370 mOsmol/kg | 4.6–5.1 | Room temperature up to 24 months | PIDD | IgA deficiency with anti-IgA antibodies; hypersensitivity | Room temp storage; higher IgA than some alternatives. Check patient IgA status | No interference | 20% SC; room temperature storage; approved for PIDD |
| Cutaquig | Octapharma | SC | Weekly | 16.5% | ≤600 mcg/mL | Maltose-free | None | 310–380 mOsmol/kg | 5.0–5.5 | Refrigerated; room temp up to 6 months | PIDD | IgA deficiency with anti-IgA antibodies; hypersensitivity | ⚠️ Higher IgA content than other SC options. Verify patient IgA antibody status | No interference | 16.5% SC; maltose-free; approved for PIDD |
| Xembify | Grifols | SC | Weekly | 20% | ≤10 mcg/mL, one of the lowest for SC products | Glycine | None | 240–300 mOsmol/kg | 4.1–4.8 | Refrigerated; room temp up to 12 months | PIDD | IgA deficiency with anti-IgA antibodies; hypersensitivity | Very low IgA, preferred SC option for IgA-sensitive patients | No interference | 20% SC; low IgA; approved for PIDD |
Related guides
Clinical data sourced from FDA-approved prescribing information. Verify current product labeling before clinical decisions.
Denied one of these medications?
Ellen can decode your denial letter, identify why you were denied, and generate a personalized appeal, free for patients.